文献速递贫血与红细胞疾病

结核病相关炎症性贫血中的铁稳态:一项前瞻性研究

Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis.
PubMed 文献 · Blood · 2021-01-01

该前瞻性研究纳入18名坦桑尼亚成人结核病患者,在治疗前及治疗26周内每2周评估铁动力学、炎症及铁代谢指标。结果显示治疗前铁吸收可忽略(<1%),完成治疗后铁吸收增加约20倍且血红蛋白增加约25%,提示铁剂补充应保留给治疗后仍贫血的患者。

要点

  • 结核相关炎症性贫血中ERFE升高但无法抑制hepcidin,铁吸收可忽略(<1%)。
  • 抗结核治疗2周后hepcidin和IL-6下降约70%,ERFE至8周才显著下降。
  • 完成治疗后铁吸收增加约20倍,血红蛋白增加约25%,铁剂应保留给治疗后仍贫血者。

核心结论

  • 结核相关炎症性贫血中升高的ERFE不能抑制hepcidin,铁吸收可忽略。
  • 治疗中炎症消退后ERFE可能持续升高,参与hepcidin抑制和血红蛋白恢复。
  • 铁仅在结核治疗完成后才良好吸收,补充应保留给治疗后仍贫血的患者。

研究设计与样本

  • 为期26周的前瞻性研究,纳入18名坦桑尼亚成人结核病患者。
  • 治疗前及治疗期间每2周评估铁动力学、炎症和铁代谢指标。
  • 治疗前、强化期(8/12周)和完成治疗(24周)时给予口服和静脉铁示踪剂。
  • 研究期间未给予铁补充剂。

主要发现

  • 治疗前hepcidin和ERFE大幅升高,红细胞铁利用率高(约80%),铁吸收可忽略(<1%)。
  • 治疗2周后hepcidin和IL-6下降约70%(P< .001),ERFE至8周才显著下降(P< .05)。
  • ERFE和IL-6是hepcidin的主要对立决定因素(P< .05),ERFE较高与网织红细胞增多和血红蛋白恢复相关(P< .01)。
  • 强化期基线示踪剂浓度稀释高2.6倍(P< .01),提示红细胞生成增强。
  • 完成治疗后铁吸收增加约20倍(P< .001),血红蛋白增加约25%(P< .001)。

临床怎么用

  • 结核相关炎症性贫血治疗期间不应常规补铁。
  • 铁剂补充应保留给完成结核治疗后仍贫血的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia of inflammation is a hallmark of tuberculosis. Factors controlling iron metabolism during anemia of inflammation and its resolution are uncertain. Whether iron supplements should be given during antituberculosis treatment to support hemoglobin (Hb) recovery is unclear. Before and during treatment of tuberculosis, we assessed iron kinetics, as well as changes in inflammation and iron metabolism indices. In a 26-week prospective study, Tanzanian adults with tuberculosis (N = 18) were studied before treatment and then every 2 weeks during treatment; oral and intravenous iron tracers were administered before treatment and after intensive phase (8/12 weeks) and complete treatment (24 weeks). No iron supplements were given. Before treatment, hepcidin and erythroferrone (ERFE) were greatly elevated, erythrocyte iron utilization was high (∼80%), and iron absorption was negligible (<1%). During treatment, hepcidin and interleukin-6 levels decreased ∼70% after only 2 weeks (P< .001); in contrast, ERFE did not significantly decrease until 8 weeks (P< .05). ERFE and interleukin-6 were the main opposing determinants of hepcidin (P< .05), and greater ERFE was associated with reticulocytosis and Hb repletion (P< .01). Dilution of baseline tracer concentration was 2.6-fold higher during intensive phase treatment (P< .01), indicating enhanced erythropoiesis. After treatment completion, iron absorption increased ∼20-fold (P< .001), and Hb increased ∼25% (P< .001). In tuberculosis-associated anemia of inflammation, our findings suggest that elevated ERFE is unable to suppress hepcidin, and iron absorption is negligible. During treatment, as inflammation resolves, ERFE may remain elevated, contributing to hepcidin suppression and Hb repletion. Iron is well absorbed only after tuberculosis treatment, and supplementation should be reserved for patients remaining anemic after treatment. This trial was registered at www.clinicaltrials.gov as #NCT02176772.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cercamondi CI, Stoffel NU, Moretti D, et al. Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis. Blood. 2021. PMID: 33876222. doi:10.1182/blood.2020010562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。